PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39707.24%
G&A change of 39707.24% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42213.03%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.21%. Jim Chanos would check for waste.
39675.25%
Total costs change of 39675.25% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
15324.18%
Interest expense change of 15324.18% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
-37386.56%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 5.24%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-5650.01%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 4.32%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-570772.46%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 1.74%. Seth Klarman would investigate advantages.
-40472.45%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 4.99%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40472.45%
Net income decline while Drug Manufacturers - Specialty & Generic median is 16.97%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-3050.00%
EPS decline while Drug Manufacturers - Specialty & Generic median is 16.67%. Seth Klarman would investigate causes.
-3050.00%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 16.67%. Seth Klarman would investigate causes.
1209.23%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.04%. Jim Chanos would check for issues.
1209.23%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.14%. Jim Chanos would check for issues.